1. Generics Bulletin
  2. >>Legal & IP

Teva Plans Action After Losing Opioids Trial In New York

Israeli Firm Is Preparing ‘Swift’ Appeal And Continues To Pursue A Mistrial

 
• By Dean Rudge

Following a mammoth six-month trial, a jury in New York has issued a verdict finding that Teva and some of its affiliates are liable for the public nuisance charges made by New York state in its opioid trial in Suffolk County State Supreme Court.

Gavel
The case involved a novel theory of liability • Source: Shutterstock: New Africa

Teva Pharmaceutical Industries Ltd. is preparing for a “swift appeal as well as continuing to pursue a mistrial” after a jury in New York held that the Israeli firm’s US affiliate did help fuel the opioid epidemic in the state. A determination for damages against Teva is set to be decided at a trial later this year.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Legal & IP

J&J Denied Injunction Over Private-Label Ustekinumab In US

 
• By Dave Wallace

Stelara originator J&J has been denied in its initial attempt to prevent Samsung Bioepis and ustekinumab biosimilar partner Sandoz from selling a private-label version of the product through a PBM in the US.

UK Forxiga SPCs Wiped Out As Trio Succeed With Plausibility Attack

 
• By Dean Rudge

Generic competition to AstraZeneca’s blockbuster SGLT2 inhibitor Forxiga (dapagliflozin) treatment for diabetes may hit England and Wales earlier than 2028 after a pair of SPCs were invalidated following proceedings initiated by a trio of generics manufacturers.

Glenmark’s UK Dapagliflozin Blocked On Appeal After Teva Readied Launch

 
• By Dean Rudge

Glenmark’s advantage for its UK generic version of AstraZeneca’s Forxiga (dapagliflozin) has quickly been snuffed out, after the originator won on appeal its request for injunctive relief.

Sandoz Admits To Widescale Infringement In Resolving US Rinvoq Patent Tussle

 
• By Dean Rudge

Sandoz has reached an agreement with AbbVie to dismiss without prejudice patent-infringement litigation involving more than 20 patents shielding the originator’s blockbuster JAK inhibitor Rinvoq.

More from Generics Bulletin